Therefore, Swertianin may impact the functionality of macrophages by activating PPARG expression, potentially offering a new mechanism for treating MASLD and mitigating lipid deposition, thereby providing novel insights for MASLD therapeutic strategies. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.